Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to United Therapeutics Corporation (NASDAQ: UTHR) filings with the U.S. Securities and Exchange Commission, along with AI-generated summaries to help interpret key disclosures. United Therapeutics is a biotechnology and pharmaceutical company whose common stock trades on the Nasdaq Global Select Market, as noted in its Form 8-K reports. The company develops therapies for pulmonary arterial hypertension and related lung diseases and pursues technologies to expand the availability of transplantable organs as part of its public benefit corporation mandate.
In these SEC filings, investors can review current reports on Form 8-K that describe material events such as quarterly earnings releases, clinical milestones, share repurchase arrangements, and shareholder meeting outcomes. For example, United Therapeutics has filed 8-Ks to furnish press releases on quarterly financial results, to report positive TETON-2 clinical data for nebulized Tyvaso in idiopathic pulmonary fibrosis, and to disclose accelerated share repurchase agreements under a board-authorized share repurchase program.
Filings also document corporate governance and compensation matters, including amendments and restatements of the company’s stock incentive plan, vote results from the annual meeting of shareholders, and the listing of common stock on the Nasdaq Global Select Market under the symbol UTHR. These documents provide insight into equity compensation structures, director elections, advisory votes on executive pay, and auditor ratification.
Through this page, you can quickly locate United Therapeutics’ 8-Ks and, where available, other forms such as 10-K annual reports, 10-Q quarterly reports, and Forms 3, 4, and 5 related to insider ownership and transactions. AI-powered summaries highlight the main points of lengthy filings, explain complex sections in simpler language, and draw attention to items that often matter to investors, such as revenue drivers, capital return actions, and significant clinical or regulatory updates. Real-time updates from EDGAR ensure that new UTHR filings appear promptly, helping users monitor the company’s regulatory and disclosure record in one place.
UNITED THERAPEUTICS director Christopher Patusky exercised stock options and sold shares in a planned transaction. He exercised 1,000 stock options at an exercise price of $101.80 per share, then sold 1,000 common shares at $578.88 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he holds 1,490 common shares directly and 1,100 shares indirectly through a trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold shares in a pre-planned transaction. She exercised 9,500 stock options for common stock at an exercise price of $146.03 per share and acquired 9,500 common shares.
On the same date, she sold 9,500 common shares in multiple open-market trades at prices between $573.9595 and $581.3325. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring on March 17, 2027 or December 31, 2026. After these transactions, she holds 40,513 shares directly, plus additional indirect holdings including 166 shares held by a spouse and 324,443 shares held by family trusts.
UNITED THERAPEUTICS Corp CFO James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in open-market transactions. The sales occurred on April 16, 2026 in multiple trades at prices reported between $573.9146 and $581.6400 per share.
The filing states that this option exercise and subsequent share sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, Edgemond directly holds 18,876 shares of Common Stock and 82,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a planned combination of option exercises and share sales. She exercised stock options for 19,000 shares of common stock at an exercise price of $146.03 per share, then sold 19,075 shares in multiple open-market trades at prices mostly around the high-$570s to low-$580s.
After these direct transactions, she holds 40,513 common shares directly. In addition, indirect holdings include shares held by family trusts and her spouse, with trust and spouse positions ranging from 10,962 to 258,117 shares as of March 13, 2026. The filing notes that the option exercises and resulting sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares in a planned transaction. As EVP & General Counsel, he exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share, then sold 8,300 shares in multiple open-market trades at weighted average prices around $574–$578 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After the trades, he directly owned 45,172 shares of United Therapeutics common stock.
Paul Mahon submitted a Form 144 notice reporting proposed sales of Common Stock, consisting of repeated blocks of 8,300 shares tied to stock option exercises. The filing lists multiple sale dates in Q1–Q2 2026 (examples: 02/05/2026, 03/05/2026, 04/02/2026, 04/16/2026).
The transactions are described as Stock Option Exercise and appear filed through Morgan Stanley Smith Barney LLC as broker. The filing is a regulatory notice of proposed resale activity, not a company operational disclosure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the corresponding common shares.
On the same date, she sold 9,500 common shares in multiple open-market transactions, with reported prices including $569.7771, $571.3888 and up to $579.5260 per share, under a pre-arranged Rule 10b5-1 trading plan. Following these trades, she holds 40,513 common shares directly, in addition to indirect holdings by her spouse and in family trusts.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. He exercised options for 10,000 shares of common stock at an exercise price of $135.42 per share and then sold 10,000 shares in open-market trades at prices ranging from about $569.28 to $580.03. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. After the sales, he directly holds 18,876 shares of United Therapeutics common stock.
United Therapeutics Chairperson and CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on April 10, 2026. The options were originally granted with an expiration date of March 15, 2027.
On the same date, she sold 9,500 shares of common stock in multiple open-market transactions at prices ranging from about $567 to $573 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she held 40,513 shares directly and also reported indirect holdings through her spouse and family trusts, including 324,518 shares held by a trust.